Onvansertib
Onvansertib (NMS-1286937) is a potent, selective, and orally bioavailable inhibitor of Polo-like kinase 1 (PLK1) with an IC50 of 2 nM. It demonstrates antitumor activity by inhibiting cancer cell proliferation in vitro and suppressing tumor growth in various in vivo xenograft models.
Product Specifications
CAS Number
1034616-18-6
Product Name Alternative
Apoptosis, inhibit, PLK, PLK3, PLK1, PLK2, Onvansertib, NMS-P937, NMS-P-937, NMS1286937, NMS-1286937, NMS-P 937, NMS 1286937, Inhibitor, Polo-like Kinase (PLK)
Field of Research
Cell Biology
Purity
97.01% (May vary between batches)
Solubility
Ethanol:10 mg/mL (18.78 mM) ; DMSO:25 mg/mL (46.95 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.76 mM) ; H2O:< 1 mg/mL (insoluble or slightly soluble)
Smiles
CN1CCN (CC1) c1ccc (OC (F) (F) F) c (Nc2ncc3CCc4c (nn (CCO) c4-c3n2) C (N) =O) c1
Molecular Formula
C24H27F3N8O3
Molecular Weight
532.52
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
